A gene expression ratio-based diagnostic test for bladder cancer

Advances and Applications in Bioinformatics and Chemistry

Volumn 2, Issue 1, 2009, Pages 17-22

  Dong, Lingsheng ^a   Bard, Andrew J ^a   Richards, William G ^a   Nitz, Matthew D ^b   Theodorescu, Dan ^b   Bueno, Raphael ^a   Gordon, Gavin J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

And diagnosis; Bladder cancer; Gene expression profiling

Indexed keywords

EID: 79251510713     PISSN: None     EISSN: 11786949     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bueno R, Loughlin KR, Powell MH, Gordon GJ. A diagnostic test for prostate cancer from gene expression profiling data. J Urol. 2004;171:903-906.
2. Gordon GJ, Deters LA, Nitz MD, Lieberman BC, Yeap BY, Bueno R. Differential diagnosis of solitary lung nodules using gene expression ratios. J Thorac Cardiovasc Surg. 2006;132:621-627.
3. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 16 2003;95:598-605.
4. Gordon GJ, Jensen RV, Hsiao L-L, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002;62:4963-4967.
5. Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev. 2003;12:905-910.
6. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005;11:4406-4414.
7. Nicholson BE, Frierson HF, Conaway MR, et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 2004;64:7813-7821.
8. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004;64:4040-4048.
9. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33:90-96.
10. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778-789.
11. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
12. Venables WN, Riley BD. Modern Applied Statistics with S-Plus. New York, NY: Springer; 1997.
13. Mengual L, Burset M, Ars E, et al. Partially degraded RNA from bladder washing is a suitable sample for studying gene expression profiles in bladder cancer. Eur Urol. 2006;50:1347-1355.
14. Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res. 2006;12:5129-5135.
15. Claeskens A, Ongenae N, Neefs JM, et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000;82:1123-1130.
16. Bando H, Matsumoto G, Bando M, et al. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res. 2002;93:389-396.
17. Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 2005;5:73.
18. White ES, Flaherty KR, Carskadon S, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9:853-860.
19. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418-427.
20. Gullans SR. Of microarrays and meandering time points. Nat Genet. 2000;26:4-5.